Update on the management of symptoms in schizophrenia: focus on amisulpride

Ann M MortimerDepartment of Psychiatry, Hertford Building, The University of Hull, Cottingham Road, Hull HU6 7RX, United KingdomAbstract: Amisulpride is an atypical antipsychotic drug with a unique receptor pharmacology which is dose dependent. It is a standard treatment in dysthymia as well as in p...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autor principal:	Ann M Mortimer
Formato:	article
Lenguaje:	EN
Publicado:	Dove Medical Press 2009
Materias:	Neurosciences. Biological psychiatry. Neuropsychiatry RC321-571 Neurology. Diseases of the nervous system RC346-429
Acceso en línea:	https://doaj.org/article/b1b61c965c4f46f789e825926785db10
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:b1b61c965c4f46f789e825926785db10
record_format	dspace
spelling	oai:doaj.org-article:b1b61c965c4f46f789e825926785db102021-12-02T03:15:55ZUpdate on the management of symptoms in schizophrenia: focus on amisulpride1176-63281178-2021https://doaj.org/article/b1b61c965c4f46f789e825926785db102009-05-01T00:00:00Zhttp://www.dovepress.com/update-on-the-management-of-symptoms-in-schizophrenia-focus-on-amisulp-a3141https://doaj.org/toc/1176-6328https://doaj.org/toc/1178-2021Ann M MortimerDepartment of Psychiatry, Hertford Building, The University of Hull, Cottingham Road, Hull HU6 7RX, United KingdomAbstract: Amisulpride is an atypical antipsychotic drug with a unique receptor pharmacology which is dose dependent. It is a standard treatment in dysthymia as well as in psychosis. Amisulpride is efficacious, effective and well tolerated in positive symptoms of schizophrenia: there is extensive evidence that it treats negative symptoms when given in low doses, although relative lack of EPS and an antidepressant effect may contribute. In first-episode patients amisulpride is an option, although there is little comparative work available. Amisulpride has the best evidence as an effective adjunct to clozapine treatment. Regarding intellectual function, amisulpride appears cognitive sparing but the clinical relevance of this remains obscure. There is evidence that amisulpride can improve social function but again there is little comparative work to demonstrate any particular advantages. Regarding the current conventional versus atypical antipsychotic controversy, amisulpride did better in switching studies and meta-analyses than in the single large pragmatic randomized trial reported to date. It is a versatile drug, and may offer advantages over other atypical antipsychotic drugs in the treatment of negative and depressive symptoms, and tolerability advantages such as the avoidance of weight gain. Essentially it rests with the treating clinician to employ a rational psychopharmacological approach towards the individual patient: there will be few circumstances in which amisulpride will not be a likely contender as a treatment choice.Keywords: amisulpride, negative symptoms, clozapine, depression&nbsp; Ann M MortimerDove Medical PressarticleNeurosciences. Biological psychiatry. NeuropsychiatryRC321-571Neurology. Diseases of the nervous systemRC346-429ENNeuropsychiatric Disease and Treatment, Vol 2009, Iss default, Pp 267-277 (2009)
institution	DOAJ
collection	DOAJ
language	EN
topic	Neurosciences. Biological psychiatry. Neuropsychiatry RC321-571 Neurology. Diseases of the nervous system RC346-429
spellingShingle	Neurosciences. Biological psychiatry. Neuropsychiatry RC321-571 Neurology. Diseases of the nervous system RC346-429 Ann M Mortimer Update on the management of symptoms in schizophrenia: focus on amisulpride
description	Ann M MortimerDepartment of Psychiatry, Hertford Building, The University of Hull, Cottingham Road, Hull HU6 7RX, United KingdomAbstract: Amisulpride is an atypical antipsychotic drug with a unique receptor pharmacology which is dose dependent. It is a standard treatment in dysthymia as well as in psychosis. Amisulpride is efficacious, effective and well tolerated in positive symptoms of schizophrenia: there is extensive evidence that it treats negative symptoms when given in low doses, although relative lack of EPS and an antidepressant effect may contribute. In first-episode patients amisulpride is an option, although there is little comparative work available. Amisulpride has the best evidence as an effective adjunct to clozapine treatment. Regarding intellectual function, amisulpride appears cognitive sparing but the clinical relevance of this remains obscure. There is evidence that amisulpride can improve social function but again there is little comparative work to demonstrate any particular advantages. Regarding the current conventional versus atypical antipsychotic controversy, amisulpride did better in switching studies and meta-analyses than in the single large pragmatic randomized trial reported to date. It is a versatile drug, and may offer advantages over other atypical antipsychotic drugs in the treatment of negative and depressive symptoms, and tolerability advantages such as the avoidance of weight gain. Essentially it rests with the treating clinician to employ a rational psychopharmacological approach towards the individual patient: there will be few circumstances in which amisulpride will not be a likely contender as a treatment choice.Keywords: amisulpride, negative symptoms, clozapine, depression&nbsp;
format	article
author	Ann M Mortimer
author_facet	Ann M Mortimer
author_sort	Ann M Mortimer
title	Update on the management of symptoms in schizophrenia: focus on amisulpride
title_short	Update on the management of symptoms in schizophrenia: focus on amisulpride
title_full	Update on the management of symptoms in schizophrenia: focus on amisulpride
title_fullStr	Update on the management of symptoms in schizophrenia: focus on amisulpride
title_full_unstemmed	Update on the management of symptoms in schizophrenia: focus on amisulpride
title_sort	update on the management of symptoms in schizophrenia: focus on amisulpride
publisher	Dove Medical Press
publishDate	2009
url	https://doaj.org/article/b1b61c965c4f46f789e825926785db10
work_keys_str_mv	AT annmmortimer updateonthemanagementofsymptomsinschizophreniafocusonamisulpride
_version_	1718401877442297856

Update on the management of symptoms in schizophrenia: focus on amisulpride

Ejemplares similares